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Abstract
The intensity of antibiotic use in hospital settings is 
recognised as possibly the most important factor for the selection 
of antimicrobial resistance. Hospitals are therefore being 
encouraged to undertake surveillance and benchmarking of 
antimicrobial consumption patterns with a view to identify and 
rectify possible evidence of overuse or misuse. Use of antibiotics 
at St. Luke’s Hospital, Malta (SLH) was assessed retrospectively 
for the year 2001 as part of participation in two pan-European 
antibiotic surveillance networks. Total antibiotic use during 
the study period averaged 147 Defined Daily Doses (DDD) 
/100 bed days with the three most common antibiotic groups 
prescribed being the penicillins, cephalosporins and macrolides. 
Combinations of penicillin with beta-lactamase inhibitor were 
the predominant antimicrobials in use and their consumption 
was twice the median for other participating hospitals in the 
European ARPAC network. Differences were additionally seen 
for second generation cephalosporins and macrolides, where 
consumption was also significantly higher at SLH. These 
findings would explain one possible factor behind the high 
prevalence of resistance, particularly in Staphylococcus aureus, 
at SLH and suggest the need to intensify efforts for improved 
antibiotic stewardship programmes in hospital prescribing.
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Introduction
The causal link between antibiotic resistance and 
consumption has been well established1. Various publications 
have documented that changes in antimicrobial usage are 
paralleled after a variable lag phase by equivalent changes in 
the prevalence of antimicrobial resistance2, and it is common 
experience within hospitals, that departments which exhibit 
the highest rates of antimicrobial resistance, also invariably 
have the highest levels of antibiotic use3. Such evidence has led 
to the hypothesis that selection of resistance during treatment 
or prophylaxis is a more important factor in the acquisition of 
infection caused by a resistant organism, than is transmission 
from patient to patient4. Consequently the intensity of antibiotic 
use in a population may actually be the most important factor 
in the selection of resistance5. As a result, numerous initiatives 
in recent years have encouraged hospitals to undertake 
surveillance of antimicrobial consumption patterns with a view 
to identify and rectify possible over-use and mis-use6. Against 
this background, a pan-European study entitled ‘Development 
of Strategies for Control and Prevention of Antibiotic Resistance 
in European Hospitals’ (Acronym: ARPAC) funded by the 
European Commission’s Research Directorate General within 
the Fifth Framework Programme was undertaken from 01 
January 2002 to 30 June 2005 [http://www.abdn.ac.uk/arpac]. 
One of the major achievements of this project was to enable 
participating hospitals to calculate their antibiotic consumption, 
to undertake benchmarking with other participating hospitals 
having a similar case-mix and in the process allow a clearer 
understanding at a local level of what drives current resistance 
problems and, importantly, what might be done to control 
them7. We report on the results of our ARPAC findings for St. 
Luke’s Hospital (SLH), an 800-bed hospital providing all public 
tertiary care in Malta, together with information also arising 
from our participation in another European Commission funded 
antibiotic surveillance network – European Surveillance of 
Antimicrobial Consumption (ESAC) [www.ua.ac.be/esac].
Methods
Antibiotic consumption statistics were obtained from 
the database maintained by the Government Pharmaceutical 
Services (GPS), the sole supplier to government dispensaries. 
This database includes all antibiotics procured by the SLH 
in-patient dispensary from GPS and therefore provided a 
comprehensive source for determining the complete antibiotic 
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use at SLH for the 12 months of the year 2001. The data was 
retrieved from its original SAGEline 100 software (version 5.20a, 
Sage UK) and converted to a text file. The file was then opened 
and subsequently saved in an Excel format (Microsoft Excel 
97, Microsoft Corp.) to allow adaptation of the in-house codes 
to the Anatomical Therapeutic Chemical (ATC) classification 
and, by further processing, converted to Defined Daily Doses 
(DDD). This methodology has been developed, validated and is 
maintained by the WHO Collaborating Centre in Oslo, Norway 
[http://www.whocc.no]. The ATC/DDD 2002 version was used 
as a reference, as set by the ARPAC protocol.
Bed day statistics were obtained from the hospital Data 
Management Unit thus allowing consumption to be reported 
in DDD per 100 bed days, a standardised figure allowing 
comparison between different institutions. Statistical analysis 
was undertaken by means of the one-sample t-test using SPSS 
software version 13 (SPSS Inc, USA).
Results
Total antibiotic use at SLH during the study period averaged 
147 DDD/100 bed days. The results indicated that the three 
most common antibiotic groups used at SLH in 2001 were 
penicillins, cephalosporins and macrolides (Table 1). Heaviest 
utilisation was evident for the penicillin group of antibiotics 
which accounted for almost a third of all antimicrobials used, 
with a consumption rate of 47.3 DDD/100 bed days. Of these, 
more than 80% were broad-spectrum penicillin plus beta-
lactamase inhibitor combinations (PBLI), which consisted 
almost exclusively of co-amoxiclav. The bulk of cephalosporin 
use was the result of cefuroxime, the only second generation 
cephalosporin in use at St. Luke’s Hospital; this accounted for 
more than half of all cephalosporin consumption. Compared to 
the beta-lactams, macrolide use was considerably less at 8.66 
DDD/100 bed days.
Several trends were apparent when the data for SLH was 
collated within the overall results of the two networks, as 
Table 1: Consumption of antibiotics within SLH 
by antimicrobial group
Antibiotic DDD/100 bed days
Penicillins (all) 47.43
• Wide spectrum 5.47
• Narrow spectrum 1.28
• Beta-lactamase stable 1.41
• With beta-lactamase inhibitor 39.26
Cephalosporins (all) 16.59
• First-generation  3.49
• Second-generation  9.67
• Third-generation  3.42
Carbapenems 1.51
Macrolides 8.66
Aminoglycosides 1.71
Quinolones 6.85
Glycopeptides 0.47
FI: Finland, FR: France, MT: Malta, BE: Belgium, PL: Poland, GR: Greece, LU: Luxembourg, HR: Croatia, SI: Slovenia, DK: Denmark, 
SK: Slovakia, SW: Sweden, HU: Hungary, NO: Norway.
Figure 1: Total antibiotic use during 2001 within hospital participating in the ESAC project (MT = Malta/SLH)
Reproduced with permission
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Figure 3:  Use of penicillin class antibiotics during 2001 within hospital 
participating in the ESAC project (MT = Malta/SLH)
Reproduced with permission
Figure 2: Antibiotic consumption of various classes in DDD/100 bed days for SLH and median consumption 
for the overall hospitals in the ARPAC study and for the sub-group of hospitals in the South of Europe
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provided through personal communications from Prof. H. 
Goossens [ESAC] and Dr. F. MacKenzie [ARPAC]. ESAC data 
for 2001 (Figure 1) indicated that per capita antibiotic use at 
SLH was second highest within the network (data from Finland 
was not directly comparable since it also included consumption 
in nursing homes). 
The local consumption of penicillins was twice as high on 
a per capita basis than the 22.06 DDD/100 bed days median 
reported in the ARPAC network (p<0.05) (Figure 2). This was 
evident when comparing with the overall project median as 
well as 24.51 DDD/100 bed days reported by the sub-group 
of hospitals from the South of Europe, which themselves 
were the group that had the highest consumption patterns. 
There was no significant difference in the consumption of 
penicillins with narrow spectrum (e.g. benzylpenicillin); wide 
spectrum (e.g. amoxicillin) or which are beta-lactamase stable 
(e.g. flucloxacillin). The difference was almost exclusively the 
result of the use of PBLI’s, specifically co-amoxiclav, which at 
39.26 DDD/100 bed days was more than three times higher 
than the overall ARPAC median and twice as much as that 
found in Southern European hospitals. The considerable local 
emphasis on wide spectrum penicillins was also apparent from 
the ESAC data which showed the proportion of PBLI’s at SLH 
to be amongst the highest in all the participating European 
hospitals (Figure 3).
On the other hand, the overall consumption of cephalosporins 
at SLH did not exhibit significant differences from the median 
ARPAC consumption although there was a considerable 
variation when compared to that reported by Northern European 
hospitals where 75% of institutions reported use levels at less 
than 10 DDD/100 bed days. What was however noted was the 
disproportionate emphasis on second generation cephalosporins 
in SLH, which, at 9.67 DDD/100 bed days, was almost three 
times higher than the median reported in the project. Similar 
differences were also found for macrolide use. On the other 
hand, SLH consumption of other antibiotic groups such as 
aminoglycosides, quinolones and carbapenems were either on 
par with the overall values reported by the ARPAC project team 
or actually lower, particularly when compared to the medians 
of Southern European participating hospitals.
Discussion
Data from the European Antimicrobial Resistance 
Surveillance System (EARSS – www.earss.rivm.nl) indicates 
Malta to have the highest per capita incidence of methicillin 
resistant Staphylococcus aureus (MRSA) bacteraemia amongst 
the participating European countries (Figure 4). Whilst the fact 
that Malta data originates from a single hospital with lower blood 
culture sampling frequencies may to some extent contribute 
to skew the data, the results nevertheless point towards a 
significant incidence of multi-resistant infections, particularly 
MRSA. In addition, there is little doubt that factors that promote 
spread of microorganisms within the hospital, particularly 
overcrowding, are important contributors to the prevalence of 
nosocomial resistant infections within SLH8.
However, it is equally probable that, as evidenced in hospitals 
in other countries, the high level of antibiotic consumption 
identified at SLH is an important driver for the advent and 
proliferation of resistance9. This situation is compounded 
by the indication from our data that this above average 
consumption of antimicrobials resides predominantly in the 
wider spectrum formulations that are known to pose a greater 
risk of the development of resistance than alternatives with a 
narrower anti-bacterial spectrum of activity10. Several studies 
have identified the development of resistance associated with 
the three antimicrobial groups showing significant differences 
in consumption at SLH; namely co-amoxiclav11, cefuroxime12, 
and macrolides13. More specifically, it would appear that their 
Figure 4: Average MRSA incidence per 1000 patient bed days in European countries participating in the EARSS network 
(MT = Malta/SLH).  Adapted with permission from EARSS Annual Report 2004.14
NO: Norway, SE: Sweden, EE: Estonia, NL: Netherlands, FI: Finland, CZ: Czech Republic, PL: Poland, HU: Hungary, BG: Bulgaria, 
LV: Latvia, RO: Romania, SI: Slovenia, SK: Slovakia, DE: Germany, ES: Spain, HR: Croatia, IT: Italy, GR: Greece, BE: Belgium, 
CY: Cyprus, UK: United Kingdom, FR: France, IE: Ireland, IL: Israel, PT: Portugal, MT: Malta
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Table 2: Key recommendations of the WHO Global 
Strategy for Containment of Antimicrobial Resistance22
1. Educate all groups of prescribers and dispensers 
(including drug sellers) in the importance of 
appropriate antimicrobial use and containment of 
antimicrobial resistance;
2. Promote targeted undergraduate and postgraduate 
educational programmes for all health care workers, 
veterinarians, prescribers and dispensers on accurate 
diagnosis and management of common infections;
3. Encourage prescribers and dispensers to educate 
patients on antimicrobial use and the importance of 
adherence to prescribed treatments;
4. Improve of antimicrobial use by supervision and 
support of clinical practices, especially diagnostic and 
treatment strategies.
5. Monitor prescribing and dispensing practices and 
utilize peer group or external standard comparisons 
to provide feedback and endorsement of appropriate 
antimicrobial prescribing;
6. Encourage development and use of guidelines and 
treatment algorithms to foster appropriate use of 
antimicrobials; 
7. Empower formulary managers to limit antimicrobial 
use to the prescription of an appropriate range of 
selected antimicrobials;
8. Link professional registration requirements for 
prescribers and dispensers to requirements for 
training and continuing education.
9. Establish effective Antibiotic Committees with 
responsibility for oversight of antimicrobial use in 
hospitals;
10. Develop and regularly update guidelines for 
antimicrobial treatment and prophylaxis, and hospital 
antimicrobial formularies;
11. Monitor antimicrobial usage, including quantity and 
patterns of use; and feed back results to prescribers; 
12. Ensure on-site availability of microbiology laboratory 
services which are appropriately matched to the level 
of the hospital (e.g. secondary, tertiary); 
13. Ensure performance and quality assurance of 
appropriate diagnostic tests, bacterial identification, 
antimicrobial susceptibility tests of key pathogens, 
and timely and relevant reporting of results.
14. Ensure that laboratory data are recorded (preferably 
on a database) and are used to produce clinically- 
and epidemiologically-useful surveillance reports 
of resistance patterns among common pathogens 
and infections in a timely manner and feed back to 
prescribers and the Infection Control Programme;
15. Make the containment of antimicrobial resistance a 
national priority through the creation of a national 
intersectoral task force to raise awareness about 
antimicrobial resistance, organise data collection and 
allocate resources to promote the implementation 
of interventions to contain resistance including 
appropriate utilisation of antimicrobial drugs, control 
and prevention of infection, and research activities.
use might be a relevant risk factor for the development of MRSA 
in hospital settings. Snowcroft and colleagues showed through 
multivariate analysis that the incidence of nosocomial MRSA rose 
with increasing use of co-amoxiclav in their institution14. Monnet 
and colleagues also identified dynamic, temporal relationships 
between monthly %MRSA and macrolide use9. Both studies 
also identified quinolone consumption as another risk factor for 
MRSA; our data, however, did not indicate local consumption 
for quinolones to be significantly higher than the other hospitals 
in the ARPAC study. Nevertheless, EARSS data have shown 
a statistically significant increasing frequency of quinolone 
resistance in local blood culture isolates of Escherichia coli over 
the past 4 years15. Furthermore, the prevalence of quinolone 
resistant E. coli in Malta was the highest in all the countries in 
the network. Dynamic selection of fluoroquinolone resistance 
has been demonstrated concurrently in both Staphylococcus 
aureus as well as E. coli16. It would therefore be reasonable to 
postulate that quinolone use, which is known to be the critical 
factor for the development of antibiotic resistance in E. coli17, 
may be equally involved in the epidemiology of MRSA in SLH.
We believe that the use of co-amoxiclav is likely to be the 
result of its excessive dependence in empiric first-line therapy. 
Macrolide consumption is probably directly linked to the first-
line therapy of community-acquired pneumonia whilst second 
generation cephalosporins are the mainstay of antimicrobial 
prophylaxis in surgery. If corrective action is to be successful, 
these are therefore the areas that need to be addressed. 
Monnet has proposed, through mathematical modelling, 
that in environments (such as SLH) where there is both a 
high prevalence of resistance as well as evidence of heavy 
antibiotic consumption, the area of improvement that is likely 
to have the biggest impact on resistance is control of antibiotic 
use18. Such improvement can be obtained through antibiotic 
stewardship programmes (Table 2) which aim to ensure that the 
use of antibiotics in hospitals is commensurate to the clinical 
circumstances and the local resistance epidemiology19. To this 
end, antimicrobial guidelines have been formulated after multi-
stakeholders consultation20. Assessment of their impact on 
consumption patterns, as well as ultimately bacterial resistance, 
should be the end goal of the immediate and longer-term 
future. In addition, concurrent evidence of antibiotic misuse 
at community level21, would suggest the need for educational 
activities on proper use of this key pharmaceutical class at both 
prescriber and user levels on a national basis.
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